Sum­it­o­mo and Ot­su­ka schiz­o­phre­nia as­set flunks PhI­II, com­pa­nies blame Covid-19 in­duced place­bo ef­fect

Sum­it­o­mo and Ot­su­ka’s schiz­o­phre­nia can­di­date ulotaront failed its Phase III test, with the com­pa­nies say­ing that the Covid-19 pan­dem­ic pushed the place­bo ef­fect to high­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER